Survival Impact of Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer
Reproductive Sciences · 2024
DOI: 10.1007/s43032-024-01687-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive Sciences, 2024. Verfasst von María Alonso-Espías und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Unit, La Paz University Hospital, Paseo de La Castellana 261, 28046, Madrid, Spain. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Sentinel Lymph Node Biopsy, Lymph Node Excision, Neoplasm Staging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
To assess whether there were statistically significant differences in terms of overall survival (OS) and progression-free survival (PFS) between pelvic lymphadenectomy (PL) and sentinel lymph node biopsy (SLNB) alone as a nodal assessment method in patients with early-stage cervical cancer (IA1 with ILV to IB2 or IIA1 of the FIGO 2018 classification). A retrospective study was conducted among patients with early-stage cervical cancer who underwent radical surgery with pelvic lymph node assessment at La Paz University Hospital between 2005 and 2022. For nodal staging, either PL, SLNB + PL, or exclusive SLNB were performed, depending on the time period. Kaplan-Meier survival curves were compared between the PL and SLNB groups. Predictors of bilateral sentinel lymph node (SLN) detection were identified with Cox proportional hazard models. Among the 128 patients included, PL ± SLNB was performed in 79 (61.7%) patients and exclusive SLNB in 49 (38.3%) patients. There was no difference between PL and SLNB in OS (log-rank 0.0730) or PFS (log-rank 0.0189). Lower limb lymphedema (LLL) was significantly lower in the SLNB group (p = 0.001). Pelvic nodal assessment with SLNB alone did not worsen survival rates compared with the standard PL in patients with early-stage cervical cancer, and it is associated with a lower rate of LLL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gynecologic Oncology Unit, La Paz University Hospital, Paseo de La Castellana 261, 28046, Madrid, Spain.
- Gynecologic Oncology Unit, Donostia University Hospital, Begiristain Doktorea Pasealekua, S/N, 20014, Donostia, Gipuzkoa, Spain. mgorostidi@sego.es.
ORCID-Profile: Mikel Gorostidi
Zitieren
APA
Alonso-Espías, M., Gorostidi, M., García-Pineda, V., Gracia, M., Diestro, M. D., Siegrist, J., Zapardiel, I., & Hernández, A. (2024). Survival Impact of Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer. Reproductive Sciences. https://doi.org/10.1007/s43032-024-01687-5
Vancouver
Alonso-Espías M, Gorostidi M, García-Pineda V, Gracia M, Diestro MD, Siegrist J, et al. Survival Impact of Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer. Reproductive Sciences. 2024. doi:10.1007/s43032-024-01687-5
BibTeX
@article{AlonsoEspas2024,
author = {Alonso-Espías, María and Gorostidi, Mikel and García-Pineda, Virginia and Gracia, Myriam and Diestro, María Dolores and Siegrist, Jaime and Zapardiel, Ignacio and Hernández, Alicia},
title = {Survival Impact of Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer},
journal = {Reproductive Sciences},
year = {2024},
doi = {10.1007/s43032-024-01687-5}
}
EUVIMED